Liof Pharma

Executive Summary

Liof Pharma is a Spanish Contract Development and Manufacturing Organization (CDMO) headquartered in Barcelona, specializing in aseptic fill-finish and lyophilization of sterile injectable biologics. Founded in 2019, the company provides end-to-end services from clinical to commercial manufacturing, focusing on complex molecules such as peptides, proteins, monoclonal antibodies, RNA, and viral vectors. Operating under both EMA and FDA regulatory standards, Liof Pharma positions itself as a reliable partner for biopharmaceutical clients seeking high-quality manufacturing capabilities. The company's expertise in lyophilization—a critical step for many sensitive biologics—addresses a growing market need as the demand for stable, long-shelf-life injectables increases. Despite being relatively young, Liof Pharma has established a presence in the competitive CDMO landscape, leveraging its specialized infrastructure and regulatory compliance to attract clients. The company's focus on complex molecules and sterile injectables aligns with industry trends, including the rise of biologics and personalized medicines, positioning it for potential growth as it expands its capacity and client base.

Upcoming Catalysts (preview)

• Q4 2026Expansion of manufacturing capacity (new lyophilization line)70% success
• H2 2026Securing a long-term contract with a major biopharma company50% success
• Q3 2026Regulatory inspection approval (EMA or FDA) for commercial production80% success